Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 9—September 2015
Emerging Infections Program

Twenty Years of Active Bacterial Core Surveillance

Gayle LangleyComments to Author , William Schaffner, Monica M. Farley, Ruth Lynfield, Nancy M. Bennett, Arthur L. Reingold, Ann Thomas, Lee H. Harrison, Megin Nichols, Susan Petit, Lisa Miller, Matthew R. Moore, Stephanie J. Schrag, Fernanda C. Lessa, Tami H. Skoff, Jessica R. MacNeil, Elizabeth Briere, Emily J. Weston, and Chris Van Beneden
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (G. Langley, M.R. Moore, S.J. Schrag, F.C. Lessa, T.H. Skoff, J.R. MacNeil, E.C. Briere, E.J. Weston, C. Van Beneden); Vanderbilt University School of Medicine, Nashville, Tennessee, USA (W. Schaffner); Emory University School of Medicine and The Atlanta VA Medical Center, Atlanta (M.M. Farley); Minnesota Department of Health, St. Paul, Minnesota, USA (R. Lynfield); University of Rochester, Rochester, New York, USA (N.M. Bennett); University of California, Berkley, California, USA (A. Reingold); Oregon Department of Human Services, Portland, Oregon, USA (A. Thomas); Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA (L.H. Harrison); New Mexico Department of Health, Santa Fe, New Mexico, USA (M. Nichols); Connecticut Department of Public Health, Hartford, Connecticut, USA (S. Petit); Colorado Department of Public Health and Environment, Denver, Colorado, USA (L. Miller)

Main Article

Table 1

Key uses and findings of Active Bacterial Core surveillance data for vaccine development, evaluation, and policy formulation*

Pathogen Vaccines Key uses and findings
Streptococcus pneumoniae
PCV7 and PCV13
Selection of serotypes included in PCV7and PCV13
Informed ACIP recommendations for children <5 y of age
Tracking postlicensure declines in cases
Documented effectiveness of PCV7
Monitoring incidence of nonvaccine serotypes
Accelerated regulatory approval of PCV13
Informed ACIP recommendations for PCV13 use in immunocompromised adults and children
Neisseria meningitidis
Conjugate vaccines, serogroup B vaccines
Informed ACIP recommendations for children 11–18 y of age
Informed ACIP recommendations for booster dose
Documented vaccine effectiveness
Informed ACIP infant meningococcal recommendations
Evaluated potential effect on serogroup B disease in United States
Haemophilus influenzae
Hib vaccine
Tracking postlicensure declines in Hib disease
Tracking shift toward non-Hib disease;
Evaluated effect of vaccine shortages
Group A Streptococcus
M-type vaccine
(under development)
Estimated degrees of protection against severe group A streptococcal infections
Group B Streptococcus
Trivalent vaccine
(under development)
Informing development of vaccine to prevent early-onset (within 1 week of life) group B streptococcal disease
Methicillin-resistant Staphylococcus aureus S. aureus vaccine
(under development) Determining population groups to target

*ACIP, Advisory Committee on Immunization Practices; Hib, H. influenzae type b vaccine; PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine. An expanded version of this table with references is available in the online Technical Appendix (

Main Article

Page created: August 12, 2015
Page updated: August 12, 2015
Page reviewed: August 12, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.